AllTrials Campaign Launches in US

AllTrials Campaign Launches in US

The UBC Therapeutics Initiative was among the 50 patient support groups, medical societies, universities and consumer groups that came together yesterday to launch the AllTrials campaign in the US and to say:

We are calling on everyone in our sector to join us in supporting the AllTrials campaign. Hundreds of thousands of patients have taken part in clinical trials which have never reported results. For every day that passes, more information is at risk of being lost forever. We have to make every clinical trial count. Join us today.”

Campaign co-founder Dr Ben Goldacre explains: “Patients want the treatments that are best for them. This needs good quality evidence on what works. Unfortunately, we now know that around half of all clinical trials, on the treatments we use today, are withheld from doctors, researchers, and patients. This makes a mockery of our efforts to make truly informed decisions. It also puts the reputation of the entire medical profession—and pharma—on the line.

We provided our bodies, our tissue samples, our data,” says patient activist AnnaMarie Ciccarella. “I’ve heard the same sentiment expressed many times from patients in clinical trials, ‘This may not help me, but it may help another person.’ It’s time to honor that sentiment.

Imagine there was an election,” says Steven Woloshin MD, a professor at the Dartmouth Institute for health policy and clinical practice. “Would you trust the results if only half of the votes were reported? Imagine if the winner of the election was the one who decided which half of the voting was reported? That would be crazy, but that’s what the situation is when trials are not reported.

Since 2013, AllTrials has won support from almost 600 patient groups, professional societies, and academic institutions, and 85 thousand members of the public. The global campaign now represents 500 million patients, and it has helped change the law in Europe so that, starting in 2016, all drug clinical trials will be publicly registered and their results reported.

Last week AllTrials announced that pharmaceutical investors representing more than $3.8 trillion in assets are supporting the campaign. Read more


To join the campaign, please sign the AllTrials petition, and be sure to get involved with the campaign as much as you can.

If you would like to sign the petition on behalf of an organisation, email your organisation’s logo and a short statement to jcockerill@senseaboutscience.org.

To make a donation to the AllTrials campaign, please click here.


Here are some useful links to related stories and editorials that have been published in the past few days:

No Comments

Post A Comment